medigraphic.com
ISSN 0188-2198 (Impreso)

2013, Número 4

<< Anterior Siguiente >>

Rev Mex Cardiol 2013; 24 (4)


Ablación septal con alcohol en la miocardiopatía hipertrófica. Experiencia de 10 años de un centro de cardiología. Resultados inmediatos y seguimiento a 12 meses

López-Aburto G, Palacios-Rodríguez JM, Cantú-Ramírez S, Galván GE, Tolosa-Dzul G, Morán- Benavente A, Ontiveros-Martínez R

Idioma: Español
Referencias bibliográficas: 23
Paginas: 189-195
Archivo PDF: 191.67 Kb.


RESUMEN

Objetivo: Conocer las características demográficas, clínicas, hemodinámicas y su evolución intrahospitalaria a mediano plazo en la miocardiopatía hipertrófica septal obstructiva. Material y métodos: Estudio observacional, longitudinal con dirección retrospectiva, descriptivo y no comparativo (serie de casos) que incluye 21 pacientes con diagnóstico de miocardiopatía hipertrófica septal obstructiva con los siguientes criterios: clase funcional III-IV de la New York Heart Association refractarios a tratamiento y/o con gradiente ≥ 30 mmHg en reposo o ≥ 60 mmHg provocado y además con movimiento sistólico anterior o insuficiencia mitral › GII esto, por ecocardiografía. Resultados: Variables demográficas: edad promedio de la cohorte fue de 50 ± 16; distribución por género: hombres n = 8 (38.1%), mujeres n = 13 (61.9%); síntomas: angor n = 9 (42.9%), disnea n = 18 (85.7), síncope n = 5 (23.8); clases funcionales (New York Heart Association) (preablación): clase funcional 3 n = 12 (57.1%), clase funcional 4 n = 1 (4.8%); uso de fármacos: BB n =15 (71.4%), Verapamil n = 13 (61.9%), IECA n = 3 (14.3%), ECG: HVI n = 17 (81%), FA n = 1 (4.8%), BCRIHH n = 3 (14.3%); ecocardiográficas: eco basal PPVI 14.9 ± 4.4 mm, SIV 22.7 ± 4.9 mm, FE 65.5 + 7%, Gte.TSVI 106.9 ± 29.9 mmHg, grado IM-3 n = 7 (33.3%), grado IM-4 n = 10 (47.6%); postintervención Eco Gte TVSI 44.6 ± 24.3 mm, grado IM-3 n = 3 (14.3%), grado IM-4 n = 1 (4.8%), alcohol 3.4 ± 0.9 mL; estancia intrahospitalaria 5.9 ± 3 días, CPK-total 1466 ± 924, CK-MB 215 ± 128; complicaciones eléctricas BAV transitorio n = 11(52.9%), MCPD n = 1 (4.8), hemodinámicas-FE basal 65.5 + 16, FE post 62.2 ± 6.5, gte basal 106.33 ± 37 mmHg, Gte-post 44 ± 34 mmhg; evolución: 1 año CF-NYHA, CF1: n = 19 (90.5%), CF2: n = 2 (9.5%), eco Gte TSVI 22.0 ± 5.7 mmHg, SIV 20.7 ± 3.1 mm, FE (68.7 ± 6.2%), IM-0 n = 11 (52.4%), IM-1 n = 6 (28.6%), IM-2 n = 4 (19%); mortalidad intrahospitalaria del 0%. Conclusión: La ablación septal con alcohol es un método que tiene una alta tasa de éxito con una mejoría en cuanto a la calidad de vida del paciente y con un índice de complicaciones baja.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Richardson P, McKenna W, Bristow M et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996; 93: 841.

  2. Maron BJ, Bonow RO, Cannon RO et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987; 316: 844.

  3. Maron BJ, Spirito P, Wesley Y, Arce J. Development or progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy: identification by two-dimensional echocardiography. N Engl J Med. 1986; 315: 610.

  4. Charron P, Dubourg O, Desnos M et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 1998; 97: 2230.

  5. Niimura H, Bachinski LL, Sangwatanaroj S et al. Mutations in the gene for cardiac myosin-binding protein C and late onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998; 338: 1248-1257.

  6. Maron BJ, Niimura H, Casey SA et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol. 2001; 38: 315.

  7. Niimura H, Patton KK, McKenna WJ et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation. 2002; 105: 446-451.

  8. Kubo T, Kitaoka H, Okawa M et al. Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac myosin-binding protein C gene among Japanese. J Am Coll Cardiol. 2005; 46: 1737-1743.

  9. Moolman JA, Reith S, Uhl K et al. A newly created splice donor site in exon 24 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation. 2000; 101: 1396-1402.

  10. Maron BJ, Casey SA, Poliac LC et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999; 281: 650-655.

  11. Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2004; 109: 452.

  12. Knight C, Kurbaan AS, Seggeweiss H et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy. Outcome of the first series of patients. Circulation. 1997; 95: 2075-2081.

  13. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998; 98: 2415-2421.

  14. Gietzen FH, Leuner CJ, Raute-Kreinsen U et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999; 20: 1342-1354.

  15. Lakkis NM, Nagueh SF, Kleiman NS et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998; 98: 1750-1755.

  16. Nagueh SF, Lakkis NM, Middleton KJ et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1999; 34: 1123-1128.

  17. Flores-Ramirez R, Lakkis NM, Middleton KJ et al. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001; 37: 208-214.

  18. Braunwald E. Induced septal infarction: a new therapeutic strategy for hypertrophic obstructive cardiomyopathy. Circulation. 1997; 95: 1981.

  19. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995; 346: 211-214.

  20. Rivera S, Sitges M, Azqueta M, Marigiliano M, Velamazán M, Miranda-Guardiola F et al. Remodelado ventricular izquierdo tras ablación septal percutánea con alcohol en pacientes con miocardiopatía hipertrófica obstructiva. Rev Esp Cardiol. 2003; 56: 1174-1181.

  21. Shamim W, Yousufuddin M, Wang D, Henein M, Seggewiss H, Flather M et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med. 2002; 347: 1326-1333.

  22. Lakkis N. New treatment methods for patients with hypertrophic obstructive cardiomyopathy. Curr Opin Cardiol. 2000; 15: 172-177.

  23. Gietzen F, Leuner C, Gerenkamp T, Kuhn H. Relief of obstruction in hypertrophic cardiomyopathy by transient occlusion of the first septal branch of the left coronary arter [resumen]. Eur Heart J. 1994; 15: 125.




2020     |     www.medigraphic.com